Collegeville, PA, United States of America

Marc Chevrier

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Location History:

  • Spring House, PA (US) (2020)
  • Collegeville, PA (US) (2015 - 2024)

Company Filing History:


Years Active: 2015-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovations of Marc Chevrier

Introduction

Marc Chevrier is a notable inventor based in Collegeville, PA, with a significant contribution to the field of biotechnology. He holds five patents that reflect his expertise and innovative spirit. His work primarily focuses on methods for treating diseases mediated by type I interferon.

Latest Patents

One of Marc Chevrier's latest patents is titled "Method of administration of an anti-IFN-α/-ω antibody." This patent outlines methods for the administration of an anti-IFN-α/-ω antibody through subcutaneous or intravenous routes in clinically proven safe amounts. Additionally, it provides methods for the safe treatment of IFN-I mediated diseases, such as systemic lupus erythematosus (SLE). Another significant patent is "Type I interferon signatures and methods of use," which describes how type I interferon signatures can be utilized to diagnose whether a patient with an IFN-I mediated disease will respond to treatment with an IFN-I inhibitor.

Career Highlights

Throughout his career, Marc Chevrier has worked with prominent companies in the biotechnology sector, including Janssen Biotech, Inc. and Human Genome Sciences, Inc. His experience in these organizations has contributed to his development as an inventor and researcher.

Collaborations

Marc has collaborated with several professionals in his field, including Kamyar Farahi and Newman Yeilding. These collaborations have likely enhanced his research and innovation efforts.

Conclusion

Marc Chevrier's contributions to biotechnology through his patents and collaborations highlight his role as an influential inventor. His work continues to impact the treatment of diseases mediated by type I interferon.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…